Focused On-demand Library for Protein crumbs homolog 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P82279

UPID:

CRUM1_HUMAN

Alternative names:

Alternative UPACC:

P82279; A2A308; B7Z5T2; B9EG71; Q5K3A6; Q5TC28; Q5VUT1; Q6N027; Q8WWY0; Q8WWY1

Background:

Protein crumbs homolog 1, encoded by the gene with accession number P82279, is pivotal in retinal development and function. It plays a crucial role in photoreceptor morphogenesis and is essential for maintaining cell polarization and adhesion in the retina. This protein's involvement in the structural integrity of retinal cells underscores its significance in visual processing.

Therapeutic significance:

Mutations in the gene encoding Protein crumbs homolog 1 are linked to severe retinal dystrophies, including Retinitis pigmentosa 12, Leber congenital amaurosis 8, and Pigmented paravenous chorioretinal atrophy. These conditions highlight the protein's critical role in retinal health and disease, making it a target for therapeutic intervention. Understanding the role of Protein crumbs homolog 1 could open doors to potential therapeutic strategies.